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Most mammalian sphingolipids contain a 4,5-(E)-double bond. We report on the chemical synthesis of a dihydroceramide
derivative that prevents the introduction of the double bond into sphingolipids. Minimal alteration of the parent structure by
formally replacing the hydrogen atoms in the 5- and in the 6-position of the sphinganine backbone by a methylene group
leads to an inhibitor of dihydroceramide desaturase in cultured cells. In the presence of 10–50 μM of compound (1), levels of
biosynthetically formed dihydroceramide and—surprisingly—also of phytoceramide are elevated at the expense of ceramide. The
cells respond to the lack of unsaturated sphingolipids by an elevation of mRNAs of enzymes required for sphingosine formation.
At the same time, the analysis of proliferation and diﬀerentiation markers indicates that the sphingolipid double bond is required
to keep the cells in a diﬀerentiated state.
1.Introduction
Most mammalian sphingolipids contain an (E)-conﬁgured
double bond between the carbon atoms C4 and C5 of
the sphingoid moiety [1–3]. This structural element is
introduced during the last step of ceramide biosynthesis by
the enzyme dihydroceramide desaturase (DES1; Scheme 1),
a protein bound to the membrane of the Endoplasmic Retic-
ulum [4–7], encoded by the DEGS1 (degenerative spermato-
cyte homolog 1) gene, and myristoylated at its N-terminus
[8]. While the mouse Des2 protein seems to have dihydroce-
ramide Δ4-desaturase and 4-hydroxylase activity, the human
homolog DES2 appears to be only a 4-hydroxylase [9].
The ﬁrst and rate-determining step of the dihydroceramide
desaturase-catalyzed reaction is the homolytic cleavage of
the C-H-bond at C-4 of the sphinganine backbone by a
non-heme oxo-diiron species [10]. The function of the
double bond within the sphingolipids is not entirely known.
Experiments, in which cell-permeable analogs of ceramide
and dihydroceramide were exogenously added to cultured
cells [11], indicated for the ﬁrst time that the double bond
is not only required for the signaling properties of ceramide,
but also for those of sphingosine-1-phosphate (review:
[12]). Dihydroceramide desaturase (Des1) knockout mice
display decreased body weight, scaly skin, hematological
abnormalities, and abnormal liver function, and die at 8
to 10 weeks after birth [13]. As an additional tool to
study the function of the 4,5-double bond of sphingolipids,
competitive inhibitors of the desaturase have been developed
that share a cyclopropene moiety in positions 4 and 5 of the
sphingoid backbone [14–18]. Dihydroceramide levels also
increase in response to resveratrol treatment [19].
2. Results and Discussion
Here, we report on the synthesis of a cyclopropane-
bearing dihydroceramide derivative that is able to inhibit the
introduction of the double bond into the sphingolipids of
cultured cells. The dihydroceramide analog (1)( S c h e m e1)
is structurally very closely related to dihydroceramide and
distinguished from it only by the presence of an additional2 Journal of Lipids
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Scheme 1: Enzymatic reaction catalyzed by dihydroceramide desaturase DES1.
methylene group. In addition, the acyl chain is shorter
than that of most endogenous ceramides to ensure suﬃ-
cient cell permeability. Since exogenously added short-chain
ceramides are converted in cells into those with endogenous
acyl chain lengths by deacylation/reacylation [20], the title
compound can behave as the inhibitor or also as the
prodrugofacyclopropanateddihydroceramideofnativeacyl
chain length. In vitro, the desaturase shows optimal activity
towards substrates with acyl chain lengths of eight carbon
atoms [4], and also inhibition by the cyclopropene-based
inhibitor is optimal with this chain length [15]. However,
nothing is known about the chain length that is actually
optimalincells.Therationalebehindthesynthesisofthetitle
compound was that enzyme-catalyzed homolytic cleavage
of the C4-H bond within the sphingoid scaﬀold of 1 and
subsequent opening of the cyclopropyl ring should lead to a
delocalized radical intermediate that might covalently bind
to and in this way inactivate the desaturase. Mechanism-
based inhibition of oxidizing enzymes by cyclopropyl-
containing substrate analogs has been described before, for
example, [21].
The synthesis of 1 (Scheme 2) started from Garner’s
serine aldehyde (2)[ 22], which was transformed into
3 by a Wittig oleﬁnation. Treatment of 3 with meta-
chloroperbenzoic acid led to a 2.8:1 diastereomeric mixture
of erythro-a n dthreo-epoxides. Pure erythro-epoxide (4)
was isolated after ﬂash chromatography and elongated with
lithiated octyne to 5.
The relative conﬁguration of the carbon atoms C2 and
C3 of erythro-5 was determined after selective cleavage
of the acetal moiety with Amberlyst 15 in methanol at
room temperature and subsequent formation of the 1,3-
isopropylidene acetal [23]. 1HNMR analysis showed a
coupling constant 3J(4,5) of 9.5Hz, which conﬁrmed the
trans-diaxial relationship of H-4 and H-5 (Scheme 3). The
threo-diastereomer had a 3J(4,5) coupling constant of about
1Hz.
After acid deprotection of erythro-5 (Scheme 2), the
homopropargylic alcohol (6) was reduced to the homoal-
lylalcohol (7) with lithium aluminium hydride. Acylation
with lauroyl chloride aﬀorded 8. Subsequent introduction
of the cyclopropane moiety by the Furukawa variant of the
Simmons-Smith reaction [24] led to two diastereomers of 1,
which could not be separated.
Since (dihydro)ceramide analogs exogenously added to
culturedcellsundergosimilarmetabolicreactionsasendoge-
nous ceramides [25], the rapid conversion of 1 by ceramide
metabolizing enzymes and termination of its eﬀect on the
desaturase system had to be expected. Compared to other
tissues, the human skin is particularly rich in ceramides [26–
28].Therefore,in this celltype, suﬃcientlyhigh steady-state-
concentrations of 1 or of a derivative of 1 generated by
de- and reacylation with endogenous fatty acids could be
expected to prevent the introduction of the double bond.
Moreover, a cell culture model of the human skin is available
and allows the analysis of markers of diﬀerentiation and
proliferation, which should be aﬀected by the presence of
sphingolipids with and without 4,5-(E)-double bond. For
these reasons we investigated 1 in cultured diﬀerentiated
humankeratinocytes[29].Aftersevendaysofdiﬀerentiation,
the cells were incubated with diﬀerent concentrations of
1 in the culture medium for 24 hours. The diﬀerentiated
keratinocytes were then metabolically labeled with l-[3-
14C] serine, the biosynthetic precursor of sphingolipids, for
72 hours. Lipids were extracted, separated by thin layer
chromatography onsilicagelplatesimpregnated withsodium
borate [30], visualized by phosphoimager analysis, and
quantiﬁed (Figure 1).
The analysis revealed a concentration-dependent de-
crease of l-[3-14C]serine incorporation into ceramide.
50μM concentration of 1 in the culture medium led to
a reduction of ceramide labeling to less than 20% of
untreated cells. Dihydroceramide labeling was increased
3.6-fold, and labeling of phytoceramide, which is formed
by 4-hydroxylation of dihydroceramide (the accumulated
desaturase substrate), was 6.3-fold elevated compared to
untreated cells. In contrast to the title compound 1, the
cyclopropene-containing inhibitor GT11 [14] did not lead to
an elevation of phytoceramide labeling (Bernadette Breiden,
personal communication). The eﬀect of 1 on dihydroce-
ramide and ceramide biosynthesis as determined by l-3-
[14C]serine labeling was conﬁrmed with N-[1-14C]octanoyl-
sphinganine, which is a cell-permeable analog of dihydro-
ceramide. Also labeling of the ceramide subspecies Cer(AS),Journal of Lipids 3
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whichconsistsofsphingosineacylatedwitha2-hydroxy-fatty
acid, was reduced. Moreover, labeling of ceramides com-
posed of 2-hydroxyfatty acids and hydroxylated sphingoid
bases (Cer(AP) and Cer(AH)) was enhanced in the presence
of 1 (data not shown). In agreement with the proposed
mechanism of action of the title compound, corresponding
dihydroceramides with cyclopropane moieties between C4
and C5, as well as between C6 and C7 of the sphinganine
backbone, were inactive (unpublished), although competi-
tive inhibition had to be expected.
Since desaturation and hydroxylation of dihydrocer-
amide should follow a similar mechanism, it is remarkable
that 1 leads to an accumulation of dihydroceramide and
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Figure 1: Incorporation of l-[3-14C]serine into ceramides of dif-
ferentiated keratinocytes in the presence of 50μMo f1. Deviations
[%] from levels obtained in untreated cells, which were cultured as
previously described [29], are shown.
phytoceramide on the expense of ceramide levels. The
keratinocyte-speciﬁc disruption of the gene encoding the
transcriptionfactorArnt inmiceledtoseveretransepidermal
water loss because of low levels of both, ceramides and
phytoceramides, and elevated concentrations of dihydro-
ceramide in the animals’ epidermis [31]. Enzymes with4 Journal of Lipids
both sphingolipid 4-desaturase and 4-hydroxylase activity
have been suggested to exist in mice [32, 33]a n dCan-
dida albicans [34]. Furthermore, a human homolog of
the mouse 4-desaturase/4-hydroxylase has been described.
Its mRNA expression was shown to be induced dur-
ing ascorbate/serum-induced diﬀerentiation of human ker-
atinocytes [35].
In order to investigate functional consequences of the
reductionof newlybiosynthesized unsaturatedsphingolipids
brought about by 1, we quantiﬁed the mRNA levels of
several proteins involved in cell diﬀerentiation and ceramide
metabolismbyreal-timepolymerasechainreaction(Figure2).
For this purpose, proliferating human keratinocytes were
preincubated with 1 for 24 hours. Diﬀerentiation was then
induced by submitting the cells to an increased calcium ion
concentration in the medium, the so-called calcium shift
[29]. Former studies already demonstrated a correlation
between mRNA and protein levels under these conditions
[36].
Figure2showsthat24hoursaftertheonsetofthecalcium
shift, the transcription levels of the suprabasal diﬀerentiation
marker genes [37], keratin 10 and proﬁlaggrin, were about
95% lower in cells treated with 1 than in untreated cells at
the same point of time. On the other hand, the transcription
level of the basal marker gene [36], keratin 14, was 40-fold
elevated. These expression patterns suggest that treatment
with 1 causes an impairment of diﬀerentiation, so that the
cells remain in a basal proliferative state. The most likely
explanation is to attribute this eﬀect to the lack of newly
synthesized sphingolipids with 4,5-double bond.
We also determined the mRNA expression of several
enzymes involved in ceramide metabolism (Figure 2). The
mRNA level of subunit 2 of serine palmitoyl transferase, the
enzyme catalyzing the rate-determining step of sphingolipid
de novo synthesis, increased more than 70-fold within 48
hours after the onset of incubation with 1, whereas the
expression in untreated keratinocytes remained low. Also,
the transcription levels of glucosylceramide-β-glucosidase
(not shown) and of acid sphingomyelinase, which produce
ceramide by the breakdown of glucosylceramide and sph-
ingomyelin, respectively, were upregulated by 1 compared
to control cells. Unexpectedly, the cells respond to an
exogenously added excess of a ceramide analog with an
upregulation of proteins required for ceramide formation.
However, also the transcription of the gene encoding acid
ceramidase that cleaves ceramide into sphingosine and fatty
acid was upregulated. These results suggest that increased
concentrationsofsaturatedsphingolipidsdirectsphingolipid
metabolism to the production of sphingosine, which can
then be phosphorylated to sphingosine-1-phosphate. In
contrast to ceramide, sphingosine-1-phosphate behaves as
a stimulator of proliferation in most cell types [12]. This
again indicates that the 4,5-double bond is required for
keratinocyte diﬀerentiation, which is disturbed by the
accumulation of ceramides saturated within the sphingoid
moiety.
Furthermore, we identiﬁed several metabolites of 1
produced by ceramide metabolizing enzymes within the
cell. The analysis was done by electrospray ionization mass
Table 1: N-acyl metabolites of 1 identiﬁed by ESI-MS in lipid
extracts of diﬀerentiated keratinocytes.
Fatty acid type m/z of molecular ion [M+H]+
14:0 440.4
16:0 468.4
16:0ha 484.4
18:0 496.4
18:1 494.4
22:0 552.4
24:1 578.5
26:0 608.5
28:1 634.5
aα-hydroxy fatty acid.
spectrometry (ESI-MS) in lipid extracts of diﬀerentiated
keratinocytes treated with 1. In this way, N-acyl metabolites
of 1,producedbyceramidase-catalyzedcleavageoftheamide
bond and subsequent acylation with diﬀerent endogenous
fatty acids, were found (Table 1). As an example, Figure 3
shows the MS/MS spectrum of the metabolite of 1 acylated
by nervonic acid. In addition, the sphingomyelin analog of
1, but not the corresponding glucosylated metabolite, could
also be identiﬁed.
In summary, we demonstrated that addition of nontoxic
concentrations of the dihydroceramide analogue 1 to cul-
tured keratinocytes reduces the introduction of the double
bond into newly synthesized sphingolipids and leads to an
impairment of diﬀerentiation. As a result, the keratinocytes
remain in a basal proliferative state. This indicates that the
double bond within the sphingoid moiety of sphingolipids is
important for the maintenance of diﬀerentiation.
Despite the apparent similarity between the title com-
pound and the family of cyclopropene-based dihydroce-
ramide desaturase inhibitors, there are principle diﬀerences
between both approaches: cyclopropenes display signiﬁcant
chemical reactivity towards nucleophiles and behave as alky-
lating agents. Cyclopropene-containing fatty acid analogs
interferewithdesaturationbyadditiontothiolgroupsofcys-
teine residues [38]. Alkyl cyclopropanes, on the other hand,
require oxidation or hydrogen abstraction in α-position for
reactivity. The cyclopropene inhibitors [14–17]a r ep o t e n t
and selective dihydroceramide desaturase inhibitors and
have been applied, for example, to analyze the function
of dihydrosphingolipids [39]. The best characterized parent
compound is a competitive inhibitor with a Ki value of
6μM[ 14]. Side eﬀects, which occur at concentrations above
5μM, such as inhibition of serine palmitoyl transferase
and accumulation of sphingoid-1-phosphates, have been
investigatedinneurons[18].Weaddinformationonthenew
title compound and demonstrate its eﬀect on diﬀerentiation
and proliferation of cultured human keratinocytes. Since
low-molecular weight sphingolipid analogs are discussed
as tools for the control of signaling and disease [40], the
title compound with only a minimal change in the dihy-
droceramide structure might be of value for the controlled
alteration of cellular properties.Journal of Lipids 5
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Figure 2: Eﬀect of 1 o nt r a n s c r i p t i o nl e v e l so fd i ﬀerentiation markers and enzymes of sphingolipid metabolism in cultured human
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3. Experimental
3.1. Analytical Data. N-((1S,2R)-(3-(2 -Hexylcyclopropyl)-
2-hydroxy-1-hydroymethyl-propyl)) dodecanamide (1): Rf
(chloroform/methanol 20:1)=0.23.
1H-NMR (300MHz, CDCl3): δ =0.15−0.31 (m, br,
2H, cyclopropyl-H), 0.36−0.55 (m, br, 2H, cyclopropyl-
H), 0.86 (t, J=6.5Hz, 6H, CH3), 1.13−1.41 (m, 28H,
CH2), 1.41−1.50 (m, br, 1H, cyclopropyl-H), 1.62 (m,
2H, CH2), 2.21 (t, J=7.5Hz, 2H, CH2CO), 2.50−2.85 (m,
br, 2H, HOCH2, 2-OH), 3.69 (dd, J=11.0Hz, J=3.0Hz,
1H, HOCHAHB), 3.81−3.90 (m, br, 2H, 1-H, 2-H),
3.95 (dd, J=11.0Hz, J=3.0Hz, 1H, HOCHAHB), 6.36 (d,
J=7.0Hz, 1H, NH). 13C-NMR (75MHz, CDCl3): δ =11.2
(11.9)(cyclopropyl-C),14.1(CH3),15.1(15.2)(cyclopropyl-
C), 18.1 (19.1) (cyclopropyl-C), 22.7−34.0 (CH2), 36.9
(CH2CO), 38.9 (3-C), 53.6 (1-C), 62.4 (HOCH2), 74.8
(2-C), 173.6 (CO). The signal duplication for the carbon
atoms of the cyclopropane ring in 5,6-position of the
dihydroceramide scaﬀold can be attributed to the formation
of two diastereomers with diﬀerent conﬁguration during the
Simmons-Smith reaction.
FAB-MS (mNBA, C25H49NO3): m/z =412 [M+H]+,
450 [M+K]+; EI-MS (HR-MS): calcd.: 411,3712, found:
411,3711.
Cell culture experiments and quantiﬁcation of mRNA
levelsviareal-timequantitativePCRwereperformedaccord-
ing to [36].
3.2. Cell Culture. Human foreskin keratinocytes were cul-
tivated according to a modiﬁed Rheinwald and Green
method [36] and grown to conﬂuence in low calcium
(0.1mM) MCDB-153 medium. Diﬀerentiation was initiated
by elevating the calcium ion concentrations to 1.1mM
(“calcium shift”) and addition of linoleic acid/BSA (10μM)
to the MCDB-153 medium. In the presence of inhibitor
1, cells were viable as determined by morphology, cell
protein content, and metabolic capability to incorporate
radiolabeled serine into sphingolipids, when compared to
untreated cells.
3.3. Ceramide Labeling. After 8 days of calcium shift, the
medium was replaced by the corresponding serine-deﬁcient
medium and l-[3-14C]serine was added (1μCi/mL medium)
after one hour. Cells were harvested 72 hours after the
addition of radiolabeled serine. 1 was dissolved in ethanol
(10mM solution) and added to the cell culture medium
24 hours before labeling. All cell culture experiments were
conducted at least in duplicate.
3.4. Lipid Extraction and Analysis. Cells were harvested
and then homogenized by sonication in water. Lipids were
extracted by addition of methanol and chloroform and
subsequent incubation at 37◦ for 24h. Lipid extracts were
desalted on LiChroprep RP-18 columns, and the incor-
porated radioactivity was quantiﬁed by liquid scintillation
counting (Packard Instruments, Tri-Carb 1600 TR). In orderJournal of Lipids 7
to quantify the relative distribution of radioactivity within
the diﬀerent ceramide subspecies, TLC separation using the
solvent systems chloroform/methanol 9:1 (v/v) on borate-
impregnated silica gel plates and phosphoimager analysis
(Fuji,FujixBAS1000)wereperformed.Ceramide(Cer(NS)),
dihydroceramide (Cer(ND)), and phytoceramide (Cer(NP))
were clearly separated by this method. To separate ceramide
subspecies, Cer(NS) and Cer(ND), from those acylated with
2-hydroxy-fatty acids (Cer(AS), Cer(AP), and Cer(AH)),
TLCs were run twice in chloroform/methanol/acetic acid
190:9:1 (v/v/v). Lipids were identiﬁed by comparing their
mobility with authentic reference standards.
3.5. Electrospray Ionization-Time of Flight-Mass Spectrome-
try. Measurements were conducted on a Q-ToF-2 Hybrid
Quadrupole-mass spectrometer with nanoﬂow interface
(Micromass) in positive or negative ion mode. Lipid extracts
were evaporated in a stream of nitrogen, dissolved in
Chloroform/Methanol 1:1 (v/v), and sonicated for ﬁve
minutes. For the suppression of sodium adducts, the sample
was mixed with an aqueous solution of 1M ammonium
acetate to a ﬁnal concentration of 50 mM. The sample
was vortexed and centrifuged. 5μL of the supernatant
were applied to precoated glass capillaries and measured
at a source temperature of 80◦C, a capillary voltage of
900–1000V, and a cone voltage of 50V. Calibration was
performed using sodium iodide (2mg/mL) and cesium
iodide (0.05mg/mL) in 1-propanol/water 1:1 (v/v). MS/MS
spectra were recorded with argon as collision gas at an argon
partial pressure of 0.7bar. Collision energies were in the
r a n g eo f3 0t o4 0e V .
3.6. RNA Extraction and Quantiﬁcation. I no r d e rt oi n v e s -
tigate the eﬀect of 1 on the diﬀerentiation of human
keratinocytes,thecellsweregrowntoconﬂuenceasdescribed
above. 24 hours before the onset of calcium shift, 1 was
added to the cell culture for preincubation. The cells were
harvested after the indicated periods of time (see Figure 2),
and total RNA was extracted using the Purescript RNA
isolation kit according to the supplier’s instructions. RNA
qualitywastestedusinga1.2%standardRNAagarosegeland
bymeasuringtheopticaldensityratioA260/A280 (≥2.0).RNA
solutionswerethendilutedto25ng/μl in sterile water treated
with diethyl pyrocarbonate (DEPC) and stored at –80◦C.
3.7. Real-Time PCR RNA Quantiﬁcation. For every gene
studied, primers were dissolved in DEPC-treated sterile
water. All ﬂuorogenic probes contained the reporter dye
FAM covalently attached to the 5 -end and the quencher dye
TAMRA covalently attached to the 3 -end. Extension from
the 3 -end was blocked by attachment of a 3 -phosphate
group.
3.8. cDNA Synthesis. The target RNA (75ng) was reverse-
transcribed using the MuLV reverse transcriptase (Applied
Biosystems) at 48◦C for 30min. The total reaction volume
was 20μL. After cDNA synthesis, reverse transcriptase was
denatured at 95◦C for 10min.
3.9. PCR Ampliﬁcation. PCR reactions were performed with
the ABI Prism 7700 sequence detection system (Applied
Biosystems). 20μl of the RT-PCR reaction from each cDNA
sample were ampliﬁed using the AmpliTaq Gold (Applied
Biosystems) in a total volume of 90μl. Each ampliﬁcation
was performed in triplicate under the following conditions:
2min at 50 ◦Ca n d1 0 m i na t9 5 ◦C, followed by a total
of 45 two-step cycles (15 s at 95◦C and 1min at 60◦C).
As an endogenous control, the porphobilinogen deaminase
(PBGD) gene mRNA was used, which was quantiﬁed in
parallel. The results were analyzed utilizing the standard
curve method as described in User Bulletin number 2 (ABI
Prism 7700 sequence detection system, Applied Biosytems).
Abbreviations
For nomenclature of epidermal ceramides, compare [26]
or [27]: N: non-hydroxy-fatty acid; A: α-hydroxy-fatty
acid; S: sphingosine; P: phytosphingosine; H: 6-hydroxy-
sphingosine; D: dihydrosphingosine (sphinganine).
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